Clinical study on cinacalcet in treatment of secondary hyperparathyroidism in hemodialysis patients

doi:10.3969/j.issn.1002-7386.2017.21.009

Abstract：Objective To investigate the clinical effects of cinacalcet on secondary hyperparathyroidism (SHPT) in patients receiving hemodialysis.Methods Ninety-eight hemodialysis patients with SHPT were divided into observation group (n=49) and control group (n=49).The patients in control group were treated by conventional therapy including phosphate binding agent and vitamin D analogue,however,the patients in observation group,on the basis of control group,were given oral cinacalcet,then the clinical effects,the serum levels of calcium,phosphorus,iPTH,ALP and renal function were observed and compared between the two groups.Results The effective rate in the observation group was 87.8%,which was significantly higher than that (67.3%) in control group (P <0.05). After treatment the serum levels of calcium were significantly increased in both groups (P<0.01),but the serum levels of phosphorus,ALP and iPTH were significantly decreased (P<0.01),moreover observation group was superior to control group(P<0.01).There were no significantly differences in BUN, Scr,and KT/V between two groups (P>0.05).The volume of parathyroid glands after treatment was obviously smaller than that before treatment in both groups (P<0.01), moreover,which in observation group was significantly smaller than that in control group (P<0.01). The incidence rate of adverse reactions in control group was 40.8%,which was significantly higher than that (14.3%) in observation group (P <0.01).Conclusion The cinacalcet has satisfactory therapeutic effects on SHPT in hemodialysis patients,which can effectively reduce the levels of parathyroid hormone,at the same time,which can decrease parathyroid gland volume,with less adverse reactions and higher fafety, therefor, which is worth using widely in clinical practice.